NEW YORK, May 5, 2022: Morgan Lewis advised Phathom Pharmaceuticals Inc. in a revenue interest financing agreement for $260 million in non-dilutive capital. The agreement provides for an upfront $100 million cash payment and an additional $160 million cash payment upon US Food and Drug Administration approval of Phathom’s investigational product, vonoprazan, for the treatment of erosive esophagitis.
Phathom is a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases.
A Morgan Lewis team of partners Conor Larkin and Greg Hartker, and associates Matthew Riehle and Anjali Deshpande represented Phathom.